Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Imagion Biosystems Ltd. ( (AU:IBX) ) just unveiled an announcement.
Imagion Biosystems has issued 8 million new ordinary shares following the conversion of notes under its agreement with Mercer Street Global Opportunity Fund, LLC. This move is part of the company’s ongoing financial strategy to support its operations and enhance its market position in the healthcare industry, particularly in the early detection of cancer.
The most recent analyst rating on (AU:IBX) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Imagion Biosystems Ltd. stock, see the AU:IBX Stock Forecast page.
More about Imagion Biosystems Ltd.
Imagion Biosystems is a company focused on advancing healthcare through its innovative MagSense® imaging technology, which aims to improve early cancer detection. The company combines biotechnology and nanotechnology to develop non-radioactive, precision diagnostic molecular imaging solutions, targeting earlier and more specific disease detection.
Average Trading Volume: 5,907,556
Technical Sentiment Signal: Sell
Current Market Cap: A$10.04M
See more data about IBX stock on TipRanks’ Stock Analysis page.